ମେଗେଷ୍ଟ୍ରୋଲ

ମେଗେଷ୍ଟ୍ରୋଲ
Clinical data
Trade namesMegace, others
SynonymsMegestrol acetate, MGA; BDH-1298; NSC-71423; SC-10363; 17α-Acetoxy-6-dehydro-6-methylprogesterone; 17α-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
AHFS/Drugs.commonograph
Pregnancy
category
  • US: X (Contraindicated)
Routes of
administration		By mouth (tablets, suspension)
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability100%[୨]
Protein binding82% to albumin,[୩] no affinity for SHBG or CBG[୨][୪]
MetabolismLiver (hydroxylation, reduction, conjugation)[୧]
Elimination half-lifeMean: 34 hours[୫]
Range: 13–105 hours[୫]
ExcretionUrine: 57–78%[୧]
Feces: 8–30%[୧]
Identifiers
  • [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
ECHA InfoCard100.020.571 Edit this at Wikidata
Chemical and physical data
FormulaC24H32O4
Molar mass୩୮୪.୫୨ g·mol−1
3D model (JSmol)
  • CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C
  • InChI=1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1
  • Key:RQZAXGRLVPAYTJ-GQFGMJRRSA-N

ମେଗେଷ୍ଟ୍ରୋଲ (MGA), ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବିକ୍ରୟ ନାମ ମେଗେସ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ମୁଖ୍ୟତଃ କ୍ୟାଚେକ୍ସିଆ ପରି ଅପଚୟ ସିଣ୍ଡ୍ରୋମଗୁଡିକର ଚିକିତ୍ସା ପାଇଁ ଭୋକ ଉଦ୍ରେକ‌କାରୀ ଭାବରେ ବ୍ୟବହୃତ ହୁଏ | [୬] ଏହା ସ୍ତନ କର୍କଟ ଏବଂ ଏଣ୍ଡୋମେଟ୍ରିଆଲ୍ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ମଧ୍ୟ ବ୍ୟବହୃତ ହୁଏ ଏବଂ ଜନ୍ମ ନିୟନ୍ତ୍ରଣରେ ବ୍ୟବହୃତ ହୁଏ ।[୬] [୭] ଜନ୍ମ ନିୟନ୍ତ୍ରଣରେ ଇଷ୍ଟ୍ରୋଜେନ୍ ସହିତ ମିଶ୍ରିତ ହୋଇଥିଲେ ମଧ୍ୟ ମେଗେଷ୍ଟ୍ରୋଲ ସାଧାରଣତ ଏକକ ଭାବରେ ପ୍ରସ୍ତୁତ କରାଯାଇଥାଏ ।[୬] [୭] ଏହା ସାଧାରଣତଃ ପାଟିରେ ଦିଆଯାଏ ।[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଓଜନ ବୃଦ୍ଧି, ଯୋନୀ ରକ୍ତସ୍ରାବ, ଅଇ, ଉଚ୍ଚ ରକ୍ତଚାପ, ଉଚ୍ଚ ରକ୍ତ ଶର୍କରା, ଏବଂ ରାସ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।[୬] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ରକ୍ତ ଜମାଟ ବାନ୍ଧିପାରେ ।[୬] ଗର୍ଭାବସ୍ଥାରେ କିମ୍ବା ସ୍ତନ୍ୟପାନ ସମୟରେ ଏହା ବ୍ୟବହାର କଲା ଶିଶୁର କ୍ଷତି କରିପାରେ ।[୬] ଏହା ଏକ ଉତ୍ପାଦିତ ପ୍ରୋଜେଷ୍ଟିନ ।[୬] ଏହା କିପରି ଓଜନ ବୃଦ୍ଧି କରିବାରେ ସାହାଯ୍ୟ କରେ, ତାହା ଅସ୍ପଷ୍ଟ ।[୬]

ମେଗେଷ୍ଟ୍ରୋଲ୍ ୧୯୫୯ ମସିହାରେ ପ୍ୟାଟେଣ୍ଟ୍ ହୋଇଥିଲା ଏବଂ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ, ବିଶେଷ ଭାବରେ ଜନ୍ମ ନିୟନ୍ତ୍ରଣ ବଟିକା ଭାବରେ ୧୯୬୩ରେ ପ୍ରବର୍ତ୍ତିତ ହୋଇଥିଲା ।[୭] [୮] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ । [୬] ଯୁକ୍ତରାଜ୍ୟରେ ୧୬୦ ମିଗ୍ରା ବିଶିଷ୍ଟ ୩୦ଟି ବଟିକାର ମୂଲ୍ୟ ୨୦୨୧ ସୁଦ୍ଧା ୨୦ ପାଉଣ୍ଡ ଅଟେ ।[୯] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୨୩ ଡଲାର ଅଟେ ।[୧୦] ଏହା ବିଶ୍ୱରେ ଅନେକ ଦେଶରେ ବିକ୍ରି ହୁଏ । [୧୧]

ଆଧାର

[ସମ୍ପାଦନା]
  1. ↑ ୧.୦ ୧.୧ ୧.୨ Canetta R, Florentine S, Hunter H, Lenaz L (September 1983). "Megestrol acetate". Cancer Treat. Rev. 10 (3): 141–57. doi:10.1016/0305-7372(83)90029-4. PMID 6352021.
  2. ↑ ୨.୦ ୨.୧ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324. Archived (PDF) from the original on 2016-08-22. Retrieved 2021-10-31.
  3. ↑ Chu YH, Li Q, Zhao ZF (April 1986). "Pharmacokinetics of megestrol acetate in women receiving IM injection of estradiol-megestrol long-acting injectable contraceptive". The Chinese Journal of Clinical Pharmacology. Archived from the original on 2021-05-25. Retrieved 2021-10-31. A radioimmunoassay (RIA), radioligand assay and equilibrium dialysis for determination of plasma and salivary megestrol acetate (MA) concentration, sex hormone binding globulin (SHBG) capacity in plasma and percentage albumin bound MA were studied in healthy women receiving single im injection of estradiol-megestrol long-acting injectable contraceptive. The results showed that after injection the concentration of plasma MA increased rapidly. The meantime of peak plasma MA level was 3rd day, there was a linear relationship between log of plasma MA concentration and time (day) after administration in all subjects, elimination phase half-life t1/2β = 14.35 ± 9.1 days. The plasma SHBG capacity significantly increased at 7th, 14th day and decreased at 21st, 29th day after injection. The percentage albumin bound MA was 82.4%. There was no specific SHBG bound MA. There was a positive correlation between the MA concentrations in saliva and those in plasma.
  4. ↑ Schindler AE, Campagnoli C, Druckmann R, et al. (December 2003). "Classification and pharmacology of progestins". Maturitas. 46 Suppl 1: S7–S16. doi:10.1016/j.maturitas.2003.09.014. PMID 14670641.
  5. ↑ ୫.୦ ୫.୧ Richard R. Barakat; Maurie Markman; Marcus Randall (2009). Principles and Practice of Gynecologic Oncology. Lippincott Williams & Wilkins. pp. 447–. ISBN 978-0-7817-7845-9. Archived from the original on 2021-06-06. Retrieved 2021-10-31.
  6. ↑ ୬.୦୦ ୬.୦୧ ୬.୦୨ ୬.୦୩ ୬.୦୪ ୬.୦୫ ୬.୦୬ ୬.୦୭ ୬.୦୮ ୬.୦୯ "Megestrol Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 February 2021. Retrieved 15 November 2021.
  7. ↑ ୭.୦ ୭.୧ ୭.୨ Lara Marks (2010). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 77–78. ISBN 978-0-300-16791-7. Archived from the original on 2021-06-18. Retrieved 2021-10-31.
  8. ↑ Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 277–. ISBN 978-1-4612-5476-8.
  9. ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 996. ISBN 978-0857114105.
  10. ↑ "Megestrol Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 16 November 2021.
  11. ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 641. ISBN 978-3-88763-075-1. Archived from the original on 26 May 2013. Retrieved 2 June 2012.